이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 악성 종양이 있는 피험자에서 PRTH-101 단일 요법 +/- Pembrolizumab에 대한 최초의 인간 연구

2026년 9월 23일 업데이트: Incendia Therapeutics

진행성 또는 전이성 고형 종양이 있는 성인에서 PRTH-101 단독 또는 펨브롤리주맙과 병용의 안전성, 약동학, 약력학 및 활성을 조사하는 공개 라벨 1상 용량 증량 및 확장 연구

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

연구 개요

상세 설명

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

PRTH-101 is a therapeutic antibody that specifically binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells from interacting with and attacking tumor cells. These "immune cell-excluded" solid tumors are resistant to attack by the immune system (as well as other existing therapies). By disabling DDR1, the collagen fibers lose alignment and loosen, creating gaps in the tumor barrier, thus allowing T-cells to enter and naturally attack the tumor.

The main question[s] it aims to answer are:

  • to evaluate the safety and tolerability of PRTH-101 as mono therapy and in combination with pembrolizumab,
  • to determine the recommended Phase 2 dose as mono therapy and in combination with pembrolizumab,
  • to evaluate anti-tumor activity of PRTH-101 as mono therapy and in combination with pembrolizumab in selected indications

연구 유형

중재적

등록 (실제)

79

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arizona
      • Scottsdale, Arizona, 미국, 85258
        • Honor Health Research Institute
    • Connecticut
      • New Haven, Connecticut, 미국, 06511
        • Yale Cancer Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • Mass General Cancer Center
    • Oregon
      • Portland, Oregon, 미국, 97213
        • Providence Cancer Institute Franz Clinic
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15232
        • University of Pittsburgh Medical Center Hillman Cancer Center
    • Tennessee
      • Nashville, Tennessee, 미국, 27232
        • Vanderbilt-Ingram Cancer Center
    • Texas
      • Houston, Texas, 미국, 77030
        • The University of Texas MD Anderson Cancer Center
      • Houston, Texas, 미국, 77054
        • NEXT Houston
      • Irving, Texas, 미국, 75039
        • Next Oncology
      • San Antonio, Texas, 미국, 78229
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Next Oncology

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Subject must be willing and able to read, understand, and sign an Informed Consent Form.

  2. Subject must be age ≥18 years.

  3. Subject has metastatic or advanced, unresectable malignancy and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed at Screening, excluding hepatocellular carcinoma, sarcomas, and gliomas.

  4. Subject has a pathologically documented advanced/unresectable or metastatic cancer that is refractory to or intolerable to or the subject is unwilling or ineligible to receive standard treatment known to confer benefit or for which no standard treatment is available.

  5. Subject must have an Eastern Cooperative Oncology Group performance status (PS) 0-1.

  6. Subject must have a predicted life expectancy of ≥3 months.

  7. Subject must have the following laboratory values (obtained ≤14 days prior to enrollment):

    1. Calculated creatinine clearance must be ≥30 mL/min by Cockcroft-Gault formula calculation
    2. Total bilirubin ≤1.5 × ULN unless has known history of Gilbert's syndrome (in which case, total bilirubin must be ≤3 × ULN)
    3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤1.5 × ULN, or ≤3 x ULN in the presence of liver metastases
    4. Hemoglobin ≥9.0 g/dL
    5. Platelets ≥100 × 109 cells/L 9
    6. Absolute neutrophil count ≥1.5 ×10 cells/L (without the use of hematopoietic growth factors)
    7. Corrected QT interval (QTc) ≤470 milliseconds (as calculated by the Fridericia correction formula)
  8. Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 3 days prior to first administration of PRTH-101.

  9. WOCBP and males with female partners of child-bearing potential must agree to use adequate birth control throughout their participation and for 90 days following the last dose of PRTH-101.

  10. Subject must be willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

  11. Subject must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines or have archived tissue available (Section 12.3) at enrollment.

    a. Subjects with sites of disease not amenable to biopsy may be considered after discussion with the Sponsor.

  12. The subject is not enrolled in any other clinical trial and is not receiving other therapy directed at their malignancy.

  13. The subject is willing to undergo pre-and post-treatment skin biopsies.

Exclusion Criteria:

  1. Subject has received prior treatment with systemic agents, including, but not limited to, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, and monoclonal antibodies (e.g., checkpoint inhibitors) within 28 days or five half-lives of the drug, whichever is shorter.

  2. Subject has ongoing toxicity from prior therapy >Grade 1 according to the CTCAE, with the following exceptions. Such exceptions must be assessed by the Investigator (and approved by the Sponsor) as not placing the subject at undue safety risk from participating in this study.

    1. Alopecia, and vitiligo
    2. Grade ≤2 neuropathy
    3. Well-controlled hypo/hyperthyroidism or other endocrinopathies that are well controlled with hormone replacement
  3. Subject has undergone a major surgery (excluding minor procedures e.g., placement of vascular access) <2 months prior to administration of PRTH-101.

  4. Subject has received radiation therapy <28 days prior to administration of PRTH-101.

    a. Exception: limited (e.g., pain palliation) radiation therapy is allowed prior to and during study treatment as long as there are no acute toxicities, and the subject has measurable disease outside the radiation field.

  5. Subject has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem-cell transplantation, at any time.

  6. Subject has a diagnosis of immunodeficiency, either primary or acquired.

  7. Subject has received treatment with systemic steroids or any other form of immunosuppressive therapy within 14 days prior to administration of PRTH-101.

    a. Exception: inhaled or topical (to include mouthwash) steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease.

  8. Subject has an active or prior history of autoimmune disease requiring immunosuppressive therapy. Exceptions can be made in discussion with the medical monitor.

  9. Subject has a known severe intolerance to or hypersensitivity reactions to monoclonal antibodies, Fc-bearing proteins (e.g., soluble receptors or other Fc fusion proteins), or IV immunoglobulin preparations; prior history of human antihuman antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

  10. Subject has Central Nervous System (CNS) tumor involvement not definitively treated with surgery or radiation that is active (including evidence of cerebral edema by MRI, or progression from prior imaging study, or has had any requirement for steroids, or clinical symptoms of/from CNS metastases within 28 days prior to study treatment.

  11. Subject has leptomeningeal carcinomatosis, regardless of treatment history.

  12. Subject has current second malignancy at other sites (exceptions: nonmelanomatous skin cancer, adequately treated in situ carcinoma [e.g., cervical], or indolent prostate cancer under observation). A history of other malignancies is allowed as long as subject has been free of recurrence for ≥2 years, or if the subject has been treated with curative intent within the past 2 years and, in the opinion of the Investigator, is unlikely to have a recurrence.

  13. Subject has active and clinically significant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or HIV (testing not required).

  14. Subject has received live vaccines within the past 30 days (inactivated vaccines are allowed; seasonal vaccines should be up to date >30 days prior to administration of PRTH-101).

  15. Women who are pregnant or breastfeeding.

  16. History of any of the following ≤6 months before first dose:

    a. Congestive heart failure New York Heart Association Grade III or IV b. Unstable angina c. Myocardial infarction d. Unstable symptomatic ischemic heart disease e. Uncontrolled hypertension despite appropriate medical therapy f. Ongoing symptomatic cardiac arrhythmias of > Grade 2 g. Symptomatic cerebrovascular events, or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy); chronic atrial fibrillation on stable anticoagulant therapy is allowed.

  17. Subject has any contraindications to the imaging assessments or other study procedures that subjects will be undergoing.

  18. Subject has any medical or social condition that, in the opinion of the Investigator, might place a subject at increased risk, affect compliance, or confound safety or other clinical study data interpretation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PRTH-101

Mono-therapy

PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

실험적: PRTH-101 with Pembrolizumab

Combo therapy

PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

PRTH-101 in combination with Pembrolizumab

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with PRTH-101
기간: Up to 4 years

To evaluate the safety of PRTH-101 as assessed by Adverse Events (AEs), including Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs)

Up to 4 years
Maximum Tolerated Dose
기간: Up to 4 years

Maximum dose level not requiring dose de-escalation under Bayesian design rules

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include the accumulation ratio.

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include PK maximum concentration (Cmax)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include observed serum concentration (Tmax)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include last measurable concentration (Clast),

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include time of last measurable concentration (Tlast,)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include area under curve up to the last measurable concentration (AUClast)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include, volume of distribution (Vd,)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include drug clearance (CL,)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1a and Phase 1b will include the time required for plasma concentration of a drug to decrease by 50% (t1⁄2.)

Up to 4 years
Anti-tumor activity of PRTH-101 alone and in combination with pembrolizumab
기간: Up to 4 years

Best overall response as assessed by iRECIST in 1c

Up to 4 years

2차 결과 측정

결과 측정
측정값 설명
기간
To evaluate the incidence and persistence of anti-PRTH-101 antibody formation and its impact on the PK profile of PRTH-101
기간: Up to 4 years

Evaluate anti-drug antibody in serum over multiple timepoints and its impact on the PK profile of PRTH-101

Up to 4 years
To evaluate the incidence and persistence of anti- PRTH-101 antibody formation and its impact on the PK profile of PRTH-101 in combination with pembrolizumab antibody therapy
기간: Up to 4 years

Evaluate anti-drug antibody in serum over multiple timepoints and its impact on the PK profile of PRTH-101 in combination with pembrolizumab antibody therapy

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include the accumulation ratio

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include PK maximum concentration (Cmax)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include observed serum concentration (Tmax)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include last measurable concentration (Clast)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include time of last measurable concentration (Tlast)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include area under curve up to the last measurable concentration (AUClast)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include volume of distribution (Vd)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include drug clearance (CL)

Up to 4 years
To evaluate the PK of pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include the time required for plasma concentration of a drug to decrease by 50% (t1⁄2.)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include accumulation ratio

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include PK maximum concentration (Cmax)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include observed serum concentration (Tmax)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include last measurable concentration (Clast)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include time of last measurable concentration (Tlast)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include area under curve up to the last measurable concentration (AUClast)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b as well as Phase 1c will include volume of distribution (Vd)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include drug clearance (CL)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
기간: Up to 4 years

PK parameters for Phase 1b will include the time required for plasma concentration of a drug to decrease by 50% (t1⁄2.)

Up to 4 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Joseph Paul Eder, MD, Incendia Therapeutics

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 3월 3일

기본 완료 (실제)

2026년 9월 2일

연구 완료 (실제)

2026년 9월 2일

연구 등록 날짜

최초 제출

2023년 2월 9일

QC 기준을 충족하는 최초 제출

2023년 2월 27일

처음 게시됨 (실제)

2023년 3월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 23일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다